WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018014111) CANCER TREATMENT AND METASTASIS INHIBITION USING AN ANTI-CANCER STEM CELL AGENT IN COMBINATION WITH A NEUL SIALIDASE INHIBITOR OR A CYTOKINE INHIBITOR AFTER PRIMARY CANCER TREATMENT
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/014111 International Application No.: PCT/CA2017/050768
Publication Date: 25.01.2018 International Filing Date: 22.06.2017
IPC:
A61K 31/616 (2006.01) ,A61K 31/155 (2006.01) ,A61K 31/215 (2006.01) ,A61K 31/635 (2006.01) ,A61K 31/7068 (2006.01) ,A61K 33/42 (2006.01) ,A61K 39/395 (2006.01) ,A61K 41/00 (2006.01) ,A61P 35/00 (2006.01) ,A61P 35/04 (2006.01) ,C07C 233/41 (2006.01) ,C07C 279/26 (2006.01) ,C07C 69/145 (2006.01) ,C07D 231/12 (2006.01) ,C07H 15/252 (2006.01) ,C07H 19/06 (2006.01) ,C07K 16/24 (2006.01) ,C12Q 1/68 (2006.01) ,G01N 33/48 (2006.01)
Applicants: HARLESS, William Warren[CA/CA]; CA
SZEWCZUK, Myron[CA/CA]; CA
Inventors: HARLESS, William Warren; CA
SZEWCZUK, Myron; CA
Agent: NORTON ROSE FULBRIGHT CANADA LLP; 1 Place Ville Marie, Suite 2500 Montreal, Québec H3B 1R1, CA
Priority Data:
62/353,34022.06.2016US
Title (EN) CANCER TREATMENT AND METASTASIS INHIBITION USING AN ANTI-CANCER STEM CELL AGENT IN COMBINATION WITH A NEUL SIALIDASE INHIBITOR OR A CYTOKINE INHIBITOR AFTER PRIMARY CANCER TREATMENT
(FR) TRAITEMENT DU CANCER ET INHIBITION DES MÉTASTASES UTILISANT UN AGENT ANTI-CELLULES SOUCHES CANCÉREUSES EN COMBINAISON AVEC UN INHIBITEUR DE LA SIALIDASE (NEUL) OU UN INHIBITEUR DE LA CYTOKINE APRÈS UN TRAITEMENT DU CANCER PRIMAIRE
Abstract:
(EN) There is provided methods, compositions and treatment regimens for treating cancer, or for inhibiting metastasis/recurrence of cancer in a patient using 1) a primary cancer treatment such as chemotherapy, and 2) within 12 to 120 hours post-primary treatment: a) a first therapeutic agent effective against cancer stem cells, such as a cytotoxic chemotherapy; and b) a second therapeutic agent that disrupts a downstream effect of a tissue repair signalling cascade induced by the primary treatment, including an inhibitor of neu- 1 sialidase such as oseltamivir phosphate, or an inhibitor of at least one cytokine associated with stem cell enrichment such as HGF, IL-6, TGF-beta, PGE-2 or PDGF-BB. There is also provided a cancer treatment with chemotherapy agent, such as a checkpoint inhibitor, in combination with either a neuraminidase 1 inhibitor such as oseltamivir phosphate, or a COX-2 inhibitor such as celecoxib, or both.
(FR) L'invention concerne des procédés, des compositions et des régimes thérapeutiques pour le traitement du cancer, ou pour l'inhibition de la métastase/récurrence du cancer chez un patient utilisant 1) un traitement du cancer primaire tel que la chimiothérapie, et 2) pendant 12 à 120 heures après le traitement primaire : a) un premier agent thérapeutique efficace contre les cellules souches cancéreuses, tel qu'une chimiothérapie cytotoxique; et b) un second agent thérapeutique qui interrompt l'effet aval d'une cascade de signalisation de réparation tissulaire induite par le traitement primaire, y compris un inhibiteur de la sialidase neu1 tel que le phosphate d'oseltamivir, ou un inhibiteur d'au moins une cytokine associée à un enrichissement de cellules souches tel que HGF, IL-6, TGF-beta, PGE -2 ou PDGF-BB. L'invention concerne également un traitement du cancer avec un agent de chimiothérapie, tel qu'un inhibiteur de point de contrôle, en combinaison avec soit un inhibiteur de la neuraminidase 1 tel que le phosphate d'oseltamivir, soit un inhibiteur de COX-2 tel que le celecoxib, ou les deux.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)